Higher Commercial Payment Rates at Private Equity–Backed Dermatology Clinics: Evidence From Transparency in Coverage Data Supplemental figure

Supplemental Figure 1. State-level median negotiated rates for (i) private practice Non-private equity vs (ii) private equity dermatology clinics in the US.
Medians shown represent median reimbursement rates for n=15 common dermatology CPT codes: biopsy procedures (11102 tangential/shave biopsy and 11104 punch biopsy) used for initial diagnosis of skin lesions; excision of lesions (11402 for benign and 11602 for malignant lesions of moderate size) for definitive treatment; intralesional injection (11900), typically for inflammatory or fibrotic conditions; wound repairs (12032 intermediate layered closure and 13132 complex repair) reflecting increasing levels of closure complexity; reconstructive tissue transfer (14060) for local flap-based defect repair; destruction of lesions (17000 for premalignant lesions such as actinic keratoses, 17110 for benign lesions, and 17261 for malignant lesions via non-excisional methods); Mohs micrographic surgery (17311 and 17313) for tissue-sparing removal of skin cancers; and outpatient evaluation and management visits (99203 new patient and 99213 established patient), representing standard office-based clinical encounters.